Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

PTC’s Phase III Data Sets Up PKU Competition With BioMarin

17 May 2023

• By Joseph Haas

Rare disease — PTC hopes to bring a competitor to BioMarin's PKU drugs to market • Source: Shutterstock

Related Content

BioMarin Expands PKU Dominion With EU Approval Of Palynziq

07 May 2019

PTC Eyes Transition From Capital-Raising To Money-Making Company

18 Aug 2020

Deal Watch: Roche And Vividion Will Investigate E3 Ligases In Cancer, Immunology

21 May 2020

Finance Watch: PTC Secures Up To $1bn In Funding From Blackstone

04 Nov 2022

PTC Confident About Commercial Prospects For Gene Therapy Upstaza

20 May 2022

Related Companies

PTC Therapeutics, Inc.

BioMarin Pharmaceutical Inc.

Censa Pharmaceuticals Inc.

Roche Holding AG

Additional Topics

Clinical Trials Rare Diseases Drug Approval Standards Business Strategies Research & Development BioPharmaceutical

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.